{"organizations": [], "uuid": "444094fe7b4999e696d0d9b9015dc2a9d06a5e88", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bavarian-nordic-collaboration-to-e/brief-bavarian-nordic-collaboration-to-evaluate-cv301-in-combination-with-durvalumab-idUSASM000JPU", "country": "US", "domain_rank": 408, "title": "BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.963, "site_type": "news", "published": "2018-02-26T17:43:00.000+02:00", "replies_count": 0, "uuid": "444094fe7b4999e696d0d9b9015dc2a9d06a5e88"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bavarian-nordic-collaboration-to-e/brief-bavarian-nordic-collaboration-to-evaluate-cv301-in-combination-with-durvalumab-idUSASM000JPU", "ord_in_thread": 0, "title": "BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Bavarian Nordic A/S:\n* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS\n* ‍BAVARIAN NORDIC AND ASTRAZENECA WILL CONTRIBUTE CLINICAL TRIAL MATERIAL AND PROVIDE FINANCIAL SUPPORT FOR PHASE 1/2​\n* ‍NEW COLLABORATION THAT WILL INVESTIGATE CV301 AND DURVALUMAB (IMFINZI(TM))​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T17:43:00.000+02:00", "crawled": "2018-02-27T15:03:03.016+02:00", "highlightTitle": ""}